ClinicalTrials.gg
Active, not recruitingNCT07128615PANDAUpdated Oct 9, 2026

A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)

A Phase 1/2 interventional study of AZD4117 and AZD5315 in Influenza A, sponsored by AstraZeneca. Active, not recruiting at 14 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Prevention

Updated Oct 9, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 45 studies in Influenza, Human by AstraZeneca — 1 open to participants now, 2 under way, 1 of them phase 3. Influenza, Human · AstraZeneca.

Enrollment
11th of 41
405 · median 300
Started
2025
the only one that year
Phase 1/2
2 of 45
none open now
Registered
45th of 45
by date

Among the 45 studies in Influenza, Human by AstraZeneca, this one is the 11th largest by enrollment of the 41 interventional ones that give a count, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 45th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 45 studies in Influenza, Human by AstraZeneca is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Influenza, Human by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of two investigational vaccines, AZD4117 and AZD5315 to protect against certain strains of avian Influenza A (H5N1 and H7N9 subtypes).

03

Conditions studied

  • Influenza A

Browse trials for

Keywords

  • Avian Influenza A
  • mRNA Vaccine
  • Pandemic Influenza
  • VLP
  • H5N1
  • H7N9
  • AstraZeneca
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Adults, ≥ 18 years of age at the time of signing the
  • Participants who are medically stable such that, according to the judgement of the Investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment
  • Written informed consent and any locally required authorization (eg, HIPAA in the US) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations

Key Exclusion Criteria:

  • History of to any component of the IMP
  • History of hypersensitivity to penicillin and its derivatives
  • History of severe adverse reaction and/or severe allergic reaction (eg, anaphylaxis associated with a vaccine
  • Known or suspected congenital or acquired immunodeficiency
  • Abnormal findings on screening laboratory tests
  • Previous history of myocarditis, pericarditis, Guillain-Barré syndrome or any other demyelinating condition
  • Known or suspected conditions as determined by history and/or physical examination
  • Receipt of any other type of seasonal influenza vaccination from 14 days before the first dose until 28 days after the administration of the last dose of IMP
  • Receipt of an mRNA vaccine within 28 days before administration of IMP
  • Receipt or expected receipt of any other type of licensed or vaccine within 28 days prior to Visit 1 (D1) or Visit 5 (D58)
  • Receipt of immunoglobulin or blood products within 6 months prior to administration of study intervention or expected receipt during the study
  • Receipt of immune-modifying drugs or therapy, such as anti-cancer chemotherapy or radiation therapy within 6 months prior to enrollment (or expected receipt during study), or long-term systemic therapy (prednisolone or equivalent at a dose of ≥ 20 mg daily for more than 2 consecutive weeks) within 6 months prior to enrollment or expected receipt during study. Topical/inhaled steroids or short-term oral steroids are permitted
  • Participation in another trial, or receiving interventional Study IMP, in the preceding 90 days or expected receipt of another study intervention (or participation in another trial) during the period of study follow-up
  • Acute (time-limited) or febrile (temperature ≥ 38.0 °C [100.4 °F]) illness/infection within 3 days of intended IMP administration
  • Individuals who have had a previous confirmed or suspected illness from influenza caused by an H5N1 or H7N9 virus
  • Individuals who had household contact with and/or intimate exposure to an individual with laboratory confirmed H5N1 infection, exposure to infected household poultry/ wild birds/cattle or contaminated environments with sick and dead poultry or wild birds or cattle, within 60 days prior to enrollment
  • Female participants who are pregnant, lactating, or of and not using a highly effective method of or abstinence from at least 4 weeks prior to IMP administration and until at least 6 months after IMP administration
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Arm 1: Dosage Level 1 (DL1) of AZD4117 18 to 64 years of age

    Participants will receive DL1 AZD4117.

    Biological: AZD4117

  • Experimental
    Arm 2: Dosage Level 2 (DL2) of AZD4117 18 to 64 years of age

    Participants will receive DL2 AZD4117.

    Biological: AZD4117

  • Experimental
    Arm 3: DL1 of AZD4117 >= 65 years of age

    Participants will receive DL1 AZD4117.

    Biological: AZD4117

  • Experimental
    Arm 4: DL2 of AZD4117 >= 65 years of age

    Participants will receive DL2 AZD4117.

    Biological: AZD4117

  • Experimental
    Arm 5: DL1 of AZD5315 18 to 64 years of age

    Participants will receive DL1 AZD5315.

    Biological: AZD5315

  • Experimental
    Arm 6: DL2 of AZD5315 18 to 64 years of age

    Participants will receive DL2 AZD5315.

    Biological: AZD5315

  • Experimental
    Arm 7: DL1 of AZD5315 >= 65 years of age

    Participants will receive DL1 AZD5315.

    Biological: AZD5315

  • Experimental
    Arm 8: DL2 of AZD5315 >= 65 years of age

    Participants will receive DL2 AZD5315.

    Biological: AZD5315

  • Placebo comparator
    Arm 9: placebo 18 to 64 years of age

    Participants will receive placebo.

    Other: Placebo

  • Placebo comparator
    Arm 10: placebo >= 65 years of age

    Participants will receive placebo.

    Other: Placebo

Interventions

  • BiologicalAZD4117

    Intramuscular (IM) injection

  • BiologicalAZD5315

    IM injection

  • OtherPlacebo

    IM injection

06

What researchers measure

Primary outcomes

  1. Percentage of participants with immediate unsolicited adverse events (AE)

    Time frame: Within 30 minutes after dosing

  2. Percentage of participants with injection site and systemic solicited adverse reactions (AR)

    Time frame: Through 7 days after dosing

  3. Percentage of participants with unsolicited AE

    Time frame: Through 28 days after the last dose

  4. Percentage of participants with serious adverse events (SAE)

    Time frame: Through 12 months after the last dose

  5. Percentage of participants with medically attended adverse events (MAAE)

    Time frame: Through 12 months after the last dose

  6. Percentage of participants with adverse events of special interest (AESI)

    Time frame: Through 12 months after the last dose

  7. Proportion of participants achieving ≥ 1:40 HAI titer post-IMP administration

    A binary endpoint, defined as ≥ 1:40 HAI titer post-IMP administration.

    Time frame: Day 58

  8. Proportion of participants achieving seroconversion post-IMP administration

    Seroconversion status, defined as either a pre-IMP administration HAI titer \< 1:10 and a post-IMP administration HAI titer ≥ 1:40, or a pre-IMP administration titer ≥ 1:10 and 4-fold increase in post-IMP administration titer.

    Time frame: Day 58

Secondary outcomes

  1. Geometric mean titer (GMT) of HAI antibody

    Time frame: Days 1 to 389

  2. Geometric mean fold-rise (GMFR) of HAI antibody titers from baseline

    The fold rise is calculated as the ratio of the post-dose titer to the pre-dose titer.

    Time frame: Days 29 to 389

  3. Proportion of participants achieving a ≥1:40 HAI titer post-IMP administration

    A binary endpoint, defined as ≥ 1:40 HAI titer post-IMP administration.

    Time frame: Days 29 to 389

  4. Proportion of participants achieving seroconversion post-IMP administration

    Seroconversion status, defined as either a pre-IMP administration HAI titer \< 1:10 and a post-IMP administration HAI titer ≥ 1:40, or a pre-IMP administration titer ≥ 1:10 and 4-fold increase in post-IMP administration titer.

    Time frame: Days 29 to 389

07

Study locations

14 sites
  • Research Site
    Long Beach, California 90815, United States
  • Research Site
    Rolling Hills Estates, California 90274, United States
  • Research Site
    Miami Lakes, Florida 33016, United States
  • Research Site
    Stockbridge, Georgia 30281, United States
  • Research Site
    Chicago, Illinois 60640, United States
  • Research Site
    Lenexa, Kansas 66219, United States
  • Research Site
    Kansas City, Missouri 64114, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Edmond, Oklahoma 73013, United States
  • Research Site
    North Charleston, South Carolina 29405, United States
  • Research Site
    Austin, Texas 78745, United States
  • Research Site
    West Jordan, Utah 84088, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Jan 2026, 4 months.

Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 4 months is below that.

Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 19, 2025
StartActual
Sep 4, 2025
Primary completionActual
Jan 28, 2026
CompletionEst.
Dec 29, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Miami Lakes, United States
Show 1 removed
  • Research Site · Hialeah, United States
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Miami Lakes, United States
    Show 1 removed
    • Research Site · Hialeah, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07128615
Lead sponsor
AstraZeneca
Collaborators
Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies
Responsible party
Sponsor
First posted
Aug 19, 2025
Start date
Sep 4, 2025
Primary completion
Jan 28, 2026
Completion
Dec 29, 2026 (estimated)
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion